- Dianthus Therapeutics, Inc. entered into an underwriting agreement on **September 9, 2025**, for a public offering of its common stock and pre-funded warrants.  **[1690585_0001193125-25-200715_d96557d8k.htm:1]** 
- The company will sell **6,487,879 shares** of common stock at a public offering price of **$33.00 per share** and pre-funded warrants to purchase **1,112,121 shares** at a public offering price of **$32.999 per pre-funded warrant**.  **[1690585_0001193125-25-200715_d96557d8k.htm:1]** **[1690585_0001193125-25-200715_d96557dex11.htm:52]** 
- The underwriters fully exercised their option to purchase an additional **1,140,000 shares** of common stock.  **[1690585_0001193125-25-200715_d96557d8k.htm:1]** **[1690585_0001193125-25-200715_d96557dex11.htm:52]** 
- The total net proceeds from the offering, including the exercised option, are expected to be approximately **$270.0 million**.  **[1690585_0001193125-25-200715_d96557d8k.htm:1]** 
- The offering is expected to close on **September 11, 2025**.  **[1690585_0001193125-25-200715_d96557d8k.htm:1]**

Dianthus Therapeutics, Inc. /DE/ (DNTH)